{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-093553","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.888182+00:00","generated_at":"2026-06-11T06:53:33.875194+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Iovance reports LN-145 + pembrolizumab 42.1% ORR in ICI-naïve mNSCLC trial","bullets":["ORR of 42.1% in ICI-naïve mNSCLC; 80% in treatment-naïve, 42.9% post-chemo, 14.3% EGFR-mutated post-TKI.","Tumor burden reduction in 76.5% of patients; durable responses deepening over time up to 15.4 months.","No new safety signals; TEAEs consistent with NMA-LD and IL-2 regimen.","Results support phase 3 study design for LN-145 in front-line mNSCLC.","Cash ~$478M (post-July offering) funds into end 2024; BLA filed for lifileucel in melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-093553","json":"https://secwatch.observer/filing/0001104659-23-093553.json","markdown":"https://secwatch.observer/filing/0001104659-23-093553.md","text":"https://secwatch.observer/filing/0001104659-23-093553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923093553/0001104659-23-093553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923093553/tm2324118d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:53:33.875194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}